Table 2.

Univariate Analysis

Median f/up in alive (n=670)	Overall	OS				PFS
Outcomes at 3 yrs	N=993	died	HR	95% CI	p	prg/died	HR	95% CI	p
Normal	869	124	Ref.			388	Ref.
High-Risk	97	53	5.96	(4.3–8.3)	<0.001	78	3.45	(2.7–4.4)	<0.001
t(11; 14)	27	7	2.7	(1.2–5.7)	0.01	14	1.9	(1.1–3.2)	0.02
Sex
M	564	109				276
F	429	75	0.9	(0.7–1.2)	0.6	204	1.02	(0.85–1.2)	0.8
Age>65
<= 65	820	152				399
> 65	173	32	1.1	(0.8–1.6)	0.6	81	1.05	(0.8–1.3)	0.7
Year of Auto-HCT
<=2005	421	89				241
> 2005	572	95	1.2	(0.9–1.6)	0.2	239	0.99	(0.8–1.2)	0.9
Months DX to Auto-HCT
<= 6 m	330	47				153
> 6 m	662	136	1.5	(1.1–2.1)	0.02	326	1.1	(0.9–1.4)	0.2
Unknown	1
Prior Auto-HCT
0	950	174	0.7	(0.4–1.4)	0.3	460	1.1	(0.7–1.7)	0.8
1	41	9				18
2	1	1				1
Unknown	1
B2 M at Auto-HCT
<=3.5	688	102
3.5–5.5	141	33	1.6	(1.1–2.4)	0.01	320	1.2	(0.9–1.5)	0.2
>5.5	86	31	2.8	(1.9–4.2)	<0.001	72	1.4	(1.04–1.9)	0.02
Unknown	78
<=3.5 vs. >3.5			0.5	(0.4–0.7)	<0.001		0.8	(0.6–0.9)	0.035
>5.5 vs. <=5.5							1.4	(1.02–1.9)	0.03
Disease Status at Transplant
Relapse	148	57	3.2	(2.3–4.4)	<0.001	107	2.5	(2.0–3.11)	<0.001
Other	845	127				373
Response prior
CR/VGPR/PR	805	127				373
MR/SD/PD/NR	181	52	1.8	(1.3–2.5)	<0.001	102	1.3	(1.06–1.6)	0.01
NE	7	5	excld			5	excld
Melphalan Alone
Yes	824	143	0.85	(0.6–1.2)	0.4	377	0.8	(0.7–1.01)	0.07
No	169	41				103